Optimizing ceftolozane-tazobactam dosage during continuous renal replacement therapy: some nuances Gerardo Aguilar 1,2,3* , Rafael Ferriols 2,3,4 , Sara Martínez-Castro 1 , Carlos Ezquer 3, 4 , Ernesto Pastor 1 , Jose A. Carbonell 1 , Manuel Alós 2,3,4 and David Navarro 2, 3, 5 We have read the recent letter by Honore et al. [1] about our findings published in this journal regarding the influence of continuous renal replacement therapy (CRRT) on the pharmacokinetics of ceftolozane-tazobactam (C/ T) [2] . In our report, we decided to administer a 3 g/iv dose every 8 h taking into account two previous studies referenced in our paper [2] and another one which showed CRRT to be an independent predictor of clinical failure (OR 4.5, 95% CI 1.18-17.39, p = 0.02) when C/T is administered at 1.5 g every 8 h [3] .
As Honore et al. explain in their paper, the C/T eliminitation was assumed by hemodiafiltration and the adsorption was not assessed [1] . However, there is a misunderstanding in this letter [1] , because we used a polysulphone membrane (Fresenius, Germany) instead of an acrylonitrile 69 Multiflow (AN-69-M). In contrast to highly adsorptive membranes (HAM; e.g., AN69 surface-treated, AN69-ST), the antibiotic adsorption with polysulphone ones is negligible, which facilitates antibiotic adaptation during CRRT [4] .
Our data should not be extrapolated to other clinical scenarios, as noted by Honore et al. [1] . In our report, ceftolozane and tazobactam plasma concentrations remained above the minimal inhibitory concentration (MIC), for MICs of up to 8 μg/mL, but we estimated that the administration of standard doses of 1 g/0.5 g, even with polysulphone membranes, could compromise the effectiveness of C/T for not reaching adequate tazobactam concentrations. Thus, the use of HAM would represent a real risk factor of clinical failure when a C/T dose of 1.5 g every 8 h is administered, especially in multidrug-resistant infections [3] . Therefore, we agree with Honore et al. [1] that therapeutic drug monitoring (TDM) is critical when using C/T for patients receiving CRRT, especially when MICs of bacteria like multidrugresistant (MDR) Pseudomonas aeruginosa are considered very high. However, the recommendation of continuous (over 24 h) vs extended (over 2 to 4 h) or intermittent (over 30 to 60 min) infusion of beta-lactams is still under debate [5] . 
